Adma Biologics Inc Год IPO
Что обозначает Год IPO в Adma Biologics Inc?
Год IPO Adma Biologics Inc является 2013
Какое определение для Год IPO?
Первичное публичное размещение акций - это тип публичного предложения, при котором акции компании обычно продаются институциональным инвесторам, которые, в свою очередь, впервые продают эти акции широкой публике на фондовой бирже.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Год IPO компаний в Health Care сектор на NASDAQ по сравнению с Adma Biologics Inc
Что делает Adma Biologics Inc?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Компании с год ipo похож на Adma Biologics Inc
- AMG Capital Trust II имеет Год IPO из 2012
- Live Nation Entertainment имеет Год IPO из 2012
- MGM Resorts International имеет Год IPO из 2012
- EnerSpar имеет Год IPO из 2012
- The Western Union имеет Год IPO из 2012
- Wameja имеет Год IPO из 2012
- Adma Biologics Inc имеет Год IPO из 2013
- Opus Bank имеет Год IPO из 2014
- Recro Pharma Inc имеет Год IPO из 2014
- Radius Recycling имеет Год IPO из 2014
- Progenity имеет Год IPO из 2014
- Axalta Coating Systems Ltd имеет Год IPO из 2014
- Anevia SA имеет Год IPO из 2014